Can-Fite Biopharma Ltd.
|Can-Fite Biopharma Ltd. Patent applications|
|Patent application number||Title||Published|
|20130345163||BIOLOGICAL MARKER FOR INFLAMMATION - Inflammatory state in a subject is assayed by determining the level of expression of A||12-26-2013|
|20120165284||PHARMACEUTICAL COMPOSITION COMPRISING A3 ADENOSINE RECEPTOR AGONIST (IB-MECA/CF-101) FOR TREATMENT OF PSORIASIS - The present invention is based on the clinical finding that twice daily administrations of 2 mg of 1-[N||06-28-2012|
|20120065155||A3 ADENOSIDE RECEPTOR AGONISTS FOR THE REDUCTION OF INTRAOCULAR PRESSURE - The present disclosure provides the use of an A3R agonist, such as IB-MECA, for reducing in a subject, preferably, human subject, intra ocular pressure (IOP). Similarly, the invention provides a pharmaceutical composition and a method for reducing IOP in a subject making use of the A||03-15-2012|
|20110144156||A3 ADENOSINE RECEPTOR ALLOSTERIC MODULATORS - Provided are 2,4-disubstituted quinoline derivatives that are A3 adenosine receptor modulators (A||06-16-2011|
|20100249053||METHOD FOR INDUCING HEPATOCYTE PROLIFERATION AND USES THEREOF - The present application provides methods and compositions for inducing hepatocyte proliferation and liver regeneration, the latter being mainly dependent on hepatocyte proliferation even if all the other cell types divide to reconstitute the organ specific-lobular-architecture. The methods and compositions provided herein make use of an A||09-30-2010|
|20100222369||TREATMENT FOR DRY EYE CONDITIONS - The present invention provides a method for treating dry eye condition in an individual comprising administrating to said individual an amount of A||09-02-2010|
Patent applications by Can-Fite Biopharma Ltd.